• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Omadacycline is noninferior to moxifloxacin in treating community acquired bacterial pneumonia

byShani ChibberandDayton McMillan
February 11, 2019
in Chronic Disease, Infectious Disease, Public Health, Pulmonology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Intensive care unit (ICU) hospitalized adults with community acquired bacterial pneumonia had comparable clinical responses when taking antibiotic courses of omadacycline, a new trial antibiotic, versus moxifloxacin.

2. The observed safety profile of omadacycline was noted to be consistent with other known tetracyclines.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Community acquired pneumonia is a common cause of hospitalization; it also has increasing rates of resistance to traditional antibiotics necessitating research for new antibiotic agents. Omadacycline is a new antibiotic from the tetracycline class, and it has in vitro activity against known pathogens commonly implicated in community acquired bacterial pneumonia. In this current study, researchers assessed the efficacy and safety profile of omadacycline versus a traditional antibiotic, moxifloxacin, among adult ICU patients with community acquired pneumonia. Overall, omadacycline was noninferior to moxifloxacin when early clinical response and overall clinical response rates were assessed, based on patient survival and symptoms. Researchers also noted that the safety profile of omadacycline was comparable to other tetracyclines.

Though results may not be generalizable to a larger patient population, this study still highlights that clinicians may be able to consider newer antibiotic agents to treat resistant bacterial community acquired pneumonia. A notable strength includes thorough microbial assessment which determined the causative pathogen in 50% of cases. This may also present a limitation as real world rates of pathogen identification are dramatically lower.

Click to read the study in the NEJM (New England Journal of Medicine)

RELATED REPORTS

Shorter antibiotic courses non-inferior for inpatient community-acquired pneumonia

Biomarkers may help guide antibiotic stewardship in community acquired pneumonia

Relevant Reading: New antibiotics for community-acquired pneumonia

In-Depth [randomized controlled trial]: This multicenter, phase III, double-blind, noninferiority randomized control trial enrolled 774 participants across 86 sites between 2015 to 2017. Patients were randomized in a 1:1 ratio to either receive 7 to 14 days of 100 mg omadacycline or 400 mg moxifloxacin (both initially administered intravenously with option to switch to oral formulation after 3 days). The primary outcome of this study was evidence of an early clinical response, assessed between 72 to 120 hours after the initial dose of antibiotics were given. Investigators assessed for symptoms of community acquired pneumonia (cough, sputum production, pleuritic chest pain, dyspnea) and measured if there was improvement in symptoms to determine if there was adequate early clinical response. Secondary endpoints included investigator-assessed clinical response at the post-treatment evaluation period (5 to 10 days after the last dose of antibiotic was given) and evidence of adverse events. Results showed that the most frequently encountered identified pathogens that caused community acquired bacterial pneumonia were Mycoplasma pneumoniae (33%). Streptococcus pneunomiae (20%), Legionella pneumophila (19%), Chlamydia pneumoniae (15%) and Haemophilus influenza (12%). Omadacycline was shown to be noninferior to moxifloxacin when early clinical response rates were measured among an intention-to-treat population (81.1% vs 82.7% respectively; -1.6 percentage difference; 95% confidence interval [CI], -7.1 to 3.8). Clinical response rates were also similar when assessed at the end of the treatment course (87.6% vs 85.1%; 2.5 percentage difference; 95% CI, -2.4 to 7.4). Adverse events occurred in 41.1% of patients in the omadacycline group and 48.5% of patients in the moxifloxacin group. The most common adverse events included gastrointestinal events, such as constipation vomiting and nausea. Severe adverse events occurred in 6.0% of omadacycline patients and in 6.7% of moxifloxacin patients, including twelve total deaths (8 in omadacycline group and 4 in the moxifloxacin group).

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: community acquired pneumoniaomadacycline
Previous Post

RNA interference agent givosiran appears safe in phase I trial

Next Post

2 Minute Medicine Rewind February 11, 2019

RelatedReports

Pneumonia collage: an older man in pajamas beside engraved lungs with a blue haze in one lower lobe and a glass with a straw
Infectious Disease

Shorter antibiotic courses non-inferior for inpatient community-acquired pneumonia

April 13, 2026
Emergency

Biomarkers may help guide antibiotic stewardship in community acquired pneumonia

August 26, 2024
Infectious Disease

High rates of diagnostic discordance in hospitalizations for community-acquired pneumonia

August 14, 2024
Emergency

Hydrocortisone reduces mortality in severe community-acquired pneumonia

June 21, 2023
Next Post

2 Minute Medicine Rewind February 11, 2019

The PIONEER-HF Trial: Sacubitril-valsartan linked to superior outcomes in acute decompensated heart failure

The PIONEER-HF Trial: Sacubitril-valsartan linked to superior outcomes in acute decompensated heart failure

Paracetamol plus ibuprofen significantly reduces post-operative morphine use in total hip arthroplasty patients

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma
  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.